Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: Results in more than 84,000 patients

European Journal of Radiology

Volumn 81, Issue 5, 2012, Pages 885-890

  Maurer, Martin ^a   Heine, Oliver ^b   Wolf, Michael ^c   Durmus, Tahir ^a   Wagner, Moritz ^a   Hamm, Bernd ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Guerbet GmbH   (Germany)

^c Michael Wolf Information Systems   (Germany)

Author keywords

Adverse events; Contrast media; Gadoteric acid (Gd DOTA); Magnetic resonance imaging; Tolerability

Indexed keywords

GADOTERATE MEGLUMINE; GADOTERIC ACID;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ALLERGY; ANAPHYLACTIC SHOCK; ARTICLE; CHILD; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIZZINESS; DYSPNEA; ERUCTATION; FEMALE; GERMANY; HEART ARREST; HEART PROARRHYTHMIA; HEAT; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IMAGE QUALITY; INCIDENCE; ISCHEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLOR; PARESTHESIA; POPULATION STRUCTURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RETCHING; RISK FACTOR; SCHOOL CHILD; SHOCK; SIDE EFFECT; SWEATING; SYNCOPE; TASTE DISCRIMINATION; URTICARIA; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMORBIDITY; CONTRAST MEDIA; DRUG TOXICITY; FEMALE; GERMANY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; NAUSEA; ORGANOMETALLIC COMPOUNDS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; URTICARIA; VOMITING; YOUNG ADULT;

EID: 84859997276     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2011.04.022     Document Type: Article

References (27)

1. Russell EJ, Geremia GK, Johnson CE, et al. Multiple cerebral metastases: detectability with Gd-DTPA-enhanced MR imaging. Radiology 1987;165(3):609-17. (Pubitemid 18003177)
2. Parizel PM, Degryse HR, Gheuens J, et al. Gadolinium-DOTA enhanced MR imaging of intracranial lesions. J Comput Assist Tomogr 1989;13(3):378-85. (Pubitemid 19141753)
3. Graif M, Bydder GM, Steiner RE, et al. Contrast-enhanced MR imaging of malignant brain tumors. AJNR Am J Neuroradiol 1985;6(6):855-62. (Pubitemid 16226994)
4. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994;190(2):417-23. (Pubitemid 24044245)
5. Marchal G, Demaerel P, Decrop E, Van Hecke P, Baert AL. Gadolinium-DOTA enhanced fast imaging of liver tumors at 1.5 T. J Comput Assist Tomogr 1990;14(2):217-22. (Pubitemid 20106408)
6. Ruehm SG, Hany TF, Pfammatter T, et al. Pelvic and lower extremity arterial imaging: diagnostic performance of three-dimensional contrast-enhanced MR angiography. AJR Am J Roentgenol 2000;174(4):1127-35. (Pubitemid 30180017)
7. Knopp MV, Balzer T, Esser M, et al. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006;41(6):491-9. (Pubitemid 44284183)
8. Herborn CU, Jäger-Booth I, Lodemann KP, Spinazzi A, Goyen M. Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance). Rofo 2009;181(7):652-7.
9. Herborn CU, Honold E, Wolf M, et al. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 2007;42(1):58-62. (Pubitemid 46072553)
10. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17(9):2359-62. (Pubitemid 44300951)
11. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243(1):148-57. (Pubitemid 46579705)
12. Bundesinstitut für Arzneimittel und Medizinprodukte. Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln (Empfehlungen zur Planung und Durchführung von Anwendungsbeobachtungen); 1998.
13. European Parliament. Directive 2001/20/EC. Off J Eur Communities 2001;L121:34-44.
14. WHO. International monitoring of adverse reactions to drugs: adverse reaction terminology. Uppsala: WHO Collaborating Centre for International Drug Monitoring; 1998.
15. Ishiguchi T, Takahashi S. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D 2010;10(3):133-45.
16. Niendorf HP, Alhassan A, Geens VR, Clauss W. Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications. Invest Radiol 1994;29(Suppl. 2):S179-82. (Pubitemid 24221100)
17. Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA. Clinical safety of gadopentetate dimeglumine. Radiology 1995;196(2):439-43.
18. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, editors. Advances in inflammation research. New York: Raven Press; 1984. p. 1-7.
19. Russell EJ, Schaible TF, Dillon W, et al. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions. AJR Am J Roentgenol 1989;152(4):813-23. (Pubitemid 19091944)
20. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 1999;10(3):477-84. (Pubitemid 29463135)
21. Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol 2001;176(6):1385-8. (Pubitemid 32510247)
22. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003;14(5):426-35. (Pubitemid 37521732)
23. Maurer M, Heine O, Wolf M, et al. Safety and tolerability of iobitridol in general and in patients with risk factors: results in more than 160000 patients. Eur J Radiol 2010;April [Epub ahead of print].
24. Oudkerk M, Sijens PE, Van Beek EJ, Kuijpers TJ. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995;30(2):75-8.
25. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-8.
26. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188(2):586-92. (Pubitemid 46167763)
27. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2(2):264-7.